Synthetic Biologics, Inc. announced that it has entered into a securities purchase agreement for the private placement of 275,000 Series C convertible preferred shares and 100,000 Series D convertible preferred shares at a price of $8 per share for gross proceeds of approximately $3 million with returning investor MSD Credit Opportunity Master Fund, L.P., a fund managed by MSD Partners, L.P. on July 28, 2022. The Series C convertible preferred shares and Series D convertible preferred shares have a conversion price of $1.22. The securities are subject to transfer restrictions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.24 USD | -2.12% | -6.61% | -44.20% |
May. 23 | Theriva Biologics Gets Fast Track Designation for Pancreatic Cancer Treatment | MT |
May. 23 | Theriva Biologics, Inc Announces U.S. Food and Drug Administration Granted Fast Track Designation | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.20% | 4.15M | |
+15.19% | 121B | |
+19.91% | 114B | |
-19.80% | 20.43B | |
-16.19% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+2.13% | 13.54B | |
+119.39% | 10.96B |
- Stock Market
- Equities
- TOVX Stock
- News Theriva Biologics, Inc.
- Theriva Biologics, Inc. announced that it expects to receive $3 million in funding from MSD Partners, L.P.